Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20076683 | 0.87 | CYP3A4 (0.37) | — | |
| SCHEMBL24931097 | 0.80 | CES2 (0.50) | CES2CES1 | |
| SCHEMBL16961740 | 0.80 | CES2 (0.33) | CES2CES1 | |
| SCHEMBL7910357 | 0.78 | VRK1 (0.34) | CES2CES1 | |
| SCHEMBL27417243 | 0.78 | HDAC1 (0.48) | CES2CES1 | |
| SCHEMBL23112583 | 0.76 | CA5A (0.46) | CES2CES1 | |
| SCHEMBL8296527 | 0.76 | KCNQ3 (0.41) | CES2CES1 | |
| SCHEMBL16954968 | 0.76 | — | — | |
| SCHEMBL14955991 | 0.75 | HPGD (0.43) | — | |
| SCHEMBL14956621 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435054-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4185386-B1 | HETEROCYCLIC INHIBITORS OF TEAD FOR TREATING CANCER | GENENTECH INC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11787775-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787775-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787775-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-116234797-A | Heterocyclic inhibitors of TEAD for the treatment of cancer | 基因泰克公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-4185386-A1 | HETEROCYCLIC INHIBITORS OF TEAD FOR TREATING CANCER | Genentech, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230054741-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230054741-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054741-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, NQO1, PCSK9 | CES2 152/4885CES1 706/4885 |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, NQO1, PCSK9 | CES2 152/4885CES1 706/4885 |
| US-11787775-B2 | Therapeutic compounds and methods of use | VHL, NQO1, PCSK9 | CES2 152/4885CES1 706/4885 |
| US-12435054-B2 | Therapeutic compounds and methods of use | VHL, NQO1, PCSK9 | CES2 152/4885CES1 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.